Washington Drug Letter

Aug. 1, 2011 | Vol. 43 No. 30

Advisory Panel Wants Tighter Bioequivalence Standards for NTIs

An FDA advisory committee recommends tighter bioequivalence standards for generic versions of narrow therapeutic index (NTI) drugs — sometimes called critical dose drugs — as small differences in dosing can lead to dangerous side effects.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

FDA Rejects Endo’s Petition to Deny Generics of Opana ER FDA Schedules Fresh Review of Avandia’s Heart Risks Surgical Implantation, Dosage Issues Raise FDA Flags Over Titan’s Anti-Opioid Drug FDA Panel Votes to Recommend More Restrictions on Hydrocodone Combos

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.